Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sunitinib malate works after stereotactic
radiosurgery in treating patients with newly diagnosed brain metastases.